Zealand Pharma A/S
NASDAQ Global SelectCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- CEO
- Emmanuel Dulac PharmD, MBA
- Full Time Employees
- 237
- Sector
- Healthcare
- Industry
- Biotechnology
- Address
- Sydmarken 11 Copenhagen Denmark 2860
- IPO Date
- Aug 9, 2017
- CIK
- 0001674988
- Website
- zealandpharma.com
- Similar Companies
- Business
- Zealand Pharma A/S, a biotechnology company focused on the discovery, design, development, and commercialization of innovative peptide-based medicines addressing unmet medical needs, operates primarily in the areas of obesity, rare diseases, and chronic inflammation. Founded in 1998 and headquartered in Søborg, Denmark, with additional operations in the United States, the company offers a pipeline of investigational candidates including petrelintide, a long-acting amylin analog for weight management; dapiglutide, a long-acting GLP-1/GLP-2 receptor dual agonist targeting obesity and low-grade inflammation; survodutide, a long-acting glucagon/GLP-1 receptor dual agonist licensed to Boehringer Ingelheim for obesity and metabolic dysfunction-associated steatohepatitis; ZP6590, a GIP receptor agonist for obesity; dasiglucagon for continuous infusion in congenital hyperinsulinism and other formulations such as Zegalogue for severe hypoglycemia; glepaglutide, a long-acting GLP-2 analog for short bowel syndrome; ZP9830, a Kv1.3 ion channel blocker for T-cell-driven autoimmune diseases; and ZP10068, a complement C3 inhibitor for complement-mediated diseases. Zealand Pharma targets patients with metabolic, gastrointestinal, and inflammatory conditions globally through research, clinical development, and strategic partnerships. In recent developments, the company entered an exclusive collaboration and licensing agreement with Roche in March 2025 to co-develop and co-commercialize petrelintide as a monotherapy and in fixed-dose combination with Roche's CT-388 for obesity, providing upfront payments of USD 1.65 billion and potential total consideration up to USD 5.3 billion; closed this agreement in May 2025 with Phase 2b ZUPREME trials advancing; submitted a Marketing Authorization Application to the European Medicines Agency for glepaglutide in short bowel syndrome; reported positive topline results from a 28-week Phase 1b trial of dapiglutide; completed an upsized equity offering raising approximately DKK 835 million in June 2024 to fund obesity programs; and appointed Steven Johnson as Chief Development Officer to strengthen leadership in obesity innovation.
Transactions in Zealand Pharma shares and/or related securities by persons discharging managerial responsibilities and/or their closely associated persons
Zealand Pharma: Transactions related to share buy-back program (week 29, 2026)
Zealand Pharma - Transactions related to share buy-back program (week 28, 2026)
Zealand Pharma - Transactions related to share buy-back program (week 28, 2026)
Zealand Pharma - Transactions related to share buy-back program (week 27, 2026)
Zealand Pharma - Transactions related to share buy-back program (week 27, 2026)
Total number of shares and voting rights in Zealand Pharma as of June 30, 2026
Zealand Pharma major shareholder announcement: The Capital Group Companies, Inc.
Zealand Pharma - Transactions related to share buy-back program (week 26, 2026)
Transactions in Zealand Pharma shares and/or related securities by persons discharging managerial responsibilities and/or their closely associated persons
Zealand Pharma - Transactions related to share buy-back program (week 25, 2026)
Zealand Pharma - Transactions related to share buy-back program (week 24, 2026)
The Next Phase Of The Obesity Drug Race
Transactions in Zealand Pharma shares and/or related securities by persons discharging managerial responsibilities and/or their closely associated persons
Transactions in Zealand Pharma shares and/or related securities by persons discharging managerial responsibilities and/or their closely associated persons
Zealand Pharma - Transactions related to share buy-back program (week 23, 2026)
Zealand Pharma increases its share capital as a result of the exercise of employee warrants
Weight loss drug maker sinks 25% after new safety data spooks investors
Zealand Pharma announces Boehringer Ingelheim's survodutide Phase III trial in people living with obesity showed targeted 34% visceral and 63% liver fat reduction, while minimizing lean mass loss in pre-specified analysis
Zealand touts promising tolerability data for obesity drug in mid-stage study